SurvivorNet on MSN
Colon cancer is not one disease: Why BRAF & KRAS mutations matter
Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.
A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
SurvivorNet on MSN
'Very promising': New cancer drug, Plixorafenib, shows promise for hard‑to‑treat brain tumors as FDA speeds its development
The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling ...
(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
Brain metastasis from melanoma is particularly deadly and options are limited due to the difficulty of breaching the brain-blood barrier. Recent research illustrated the potent and prolonged antitumor ...
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results